Skip to main content
SpringerLink
Log in

Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

We previously reported that hairy cell leukemia (HCL) patients have high percentages of CD56+/CD57+/CD3+ large granular lymphocytes consistent with cytotoxic T-lymphocytes (CTLs), and other investigators have reported skewing of the T-cell repertoire. In previous studies of up to seven HCL patients, many of the 22 established T-cell receptor (TCR) beta variable region (TRBV) families showed mono- or oligoclonal restriction. To determine whether percentages of CTLs are correlated with TRBV clonal excess, we studied 20 HCL patients with flow cytometry, PCR of TCR gamma and TRBV regions, and fractional gel electrophoresis of PCR-amplified TRBV CDR3 domains (CDR3 spectratyping). Increased percentages of CD3+/CD8+/CD57+ CTLs correlated with more mono/oligoclonal and fewer polyclonal TRBV families (r=0.53; P=0.016). Age correlated with number of mono/oligoclonal TRBV families (r=0.51; P=0.022). Time since last purine analog therapy correlated with number of polyclonal TRBV families (r=0.46; P=0.040), but treatment with the anti-CD22 recombinant immunotoxin BL22 was not related to clonal excess. We conclude that abnormalities in the T-cell repertoire in HCL patients may represent deficient immunity, and may be exacerbated by purine analogs. Increased CD3+/CD57+ T-cells may be a useful marker of abnormal TRBV repertoire in HCL patients, and might prove useful in deciding whether patients should receive biologic antibody-based treatment rather than repeated courses of purine analog for relapsed disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Goodman GR, Bethel KJ, Saven A (2003) Hairy cell leukemia: an update. Curr Opin Hematol 10:258–266

    Article  PubMed  Google Scholar 

  2. Polliack A (2002) Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders discussion (449–350). Rev Clin Exp Hematol 6:366–388

    Article  PubMed  Google Scholar 

  3. Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, Saven A, Piro LD (1993) Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277–1287

    PubMed  CAS  Google Scholar 

  4. Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D (1994) The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 14(Suppl 1):57–61

    PubMed  Google Scholar 

  5. Juliusson G, Liliemark J (1992) Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2’-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79:888–894

    PubMed  CAS  Google Scholar 

  6. Hoffman MA, Janson D, Rose E, Rai KR (1997) Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15:1138–1142

    PubMed  CAS  Google Scholar 

  7. Blasinska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urbanska-Rys H (1997) Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine–a report of three cases. Leuk Lymphoma 25:381–385

    PubMed  CAS  Google Scholar 

  8. Matutes E, Wotherspoon A, BritoBabapulle V, Catovsky D (2001) The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15:184–186

    Article  PubMed  CAS  Google Scholar 

  9. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Huchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981–2986

    PubMed  CAS  Google Scholar 

  10. Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17:45–51

    Article  PubMed  CAS  Google Scholar 

  11. Goodman GR, Burian C, Koziol JA, Saven A (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21:891–896

    Article  PubMed  Google Scholar 

  12. Tallman MS, Peterson LC, Hakimian D, Gillis S, Polliack A (1999) Treatment of hairy-cell leukemia: current views. Semin Hematol 36:155–163

    PubMed  CAS  Google Scholar 

  13. Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918–1926

    PubMed  CAS  Google Scholar 

  14. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, Tallman M, Annino L, Connors J, Coiffier B, Lauria F (1998) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 16:3007–3015

    PubMed  CAS  Google Scholar 

  15. Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P, Sokal C, Martiat P, Michaux JL (1994) A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153–1156

    PubMed  CAS  Google Scholar 

  16. Carbone A, Reato G, Di Celle PF, Lauria F, Foa R (1994) Disease eradication in hairy cell leukemia patients treated with 2- chlorodeoxyadenosine [letter]. Leukemia 8:2019–2020

    PubMed  CAS  Google Scholar 

  17. Seymour JF, Kurzrock R, Freireich EJ, Estey EH (1994) 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906–2911

    PubMed  CAS  Google Scholar 

  18. Seymour JF, Talpaz M, Kurzrock R (1997) Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7- year follow-up. Leukemia 11:42–47

    Article  PubMed  CAS  Google Scholar 

  19. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foa R (2001) Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86:1046–1050

    PubMed  CAS  Google Scholar 

  20. Hagberg H, Lundholm L (2001) Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115:609–611

    Article  PubMed  CAS  Google Scholar 

  21. Nieva J, Bethel K, Saven A (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102:810–813

    Article  PubMed  CAS  Google Scholar 

  22. Thomas DA, O’Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood 102:3906–3911

    Article  PubMed  CAS  Google Scholar 

  23. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, Fitzgerald DJ, Wilson WH, Pastan I (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729

    Article  PubMed  CAS  Google Scholar 

  24. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. New Engl J Med 345:241–247

    Article  PubMed  CAS  Google Scholar 

  25. Ruco LP, Procopio A, Maccallini V, Calogero A, Uccini S, Annino L, Mandelli F, Baroni CD (1983) Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 61:1132–1137

    PubMed  CAS  Google Scholar 

  26. Smith BR, Rosenthal DS, Ault KA (1985) Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity. Exp Hematol 13:189–193

    PubMed  CAS  Google Scholar 

  27. Bassan R, Rambaldi A, Allavena P, Abbate M, Marini B, Barbui T (1988) Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy. Am J Hematol 29:85–93

    Article  PubMed  CAS  Google Scholar 

  28. Airo P, Rossi G, Facchetti F, Marocolo D, Garza L, Lanfranchi A, Prati E, Brugnoni D, Malacarne F, Cattaneo R (1995) Monoclonal expansion of large granular lymphocytes with a CD4+ CD8dim+/− phenotype associated with hairy cell leukemia. Haematologica 80:146–149

    PubMed  CAS  Google Scholar 

  29. Kluin-Nelemans JC, Kester MG, Melenhorst JJ, Landegent JE, van de Corput L, Willemze R, Falkenburg JH (1996) Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood 87:3795–3802

    PubMed  CAS  Google Scholar 

  30. Kluin-Nelemans HC, Kester MG, van deCorput L, Boor PP, Landegent JE, van Dongen JJ, Willemze R, Falkenburg JH (1998) Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. Blood 91:4224–4231

    PubMed  CAS  Google Scholar 

  31. Spaenij-Dekking EH, Van der Meijden ED, Falkenburg JH, Kluin-Nelemans JC (2004) Clonally expanded T cells in hairy cell leukemia patients are not leukemia specific. Leukemia 18:176–178

    Article  PubMed  CAS  Google Scholar 

  32. van de Corput L, Kluin-Nelemans HC, Kester MG, Willemze R, Falkenburg JH (1999) Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones. Blood 93:251–259

    PubMed  Google Scholar 

  33. Spaenij-Dekking EH, Van Delft J, Van Der Meijden E, Hiemstra HS, Falkenburg JH, Koning F, Drijfhout JW, Kluin-Nelemans JC (2003) Synaptojanin 2 is recognized by HLA class II-restricted hairy cell leukemia-specific T cells. Leukemia 17:2467–2473

    Article  PubMed  CAS  Google Scholar 

  34. Xie XY, Sorbara L, Kreitman RJ, Fukushima PI, Kingma DW, Stetler-Stevenson M (2000) Development of lymphoproliferative disorder of granular lymphocytes in association with hairy cell leukemia. Leukemia & Lymphoma 37:97–104

    CAS  Google Scholar 

  35. McCarthy KP, Sloane JP, Kabarowski JH, Matutes E, Wiedemann LM (1992) A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol 1:173–179

    Article  PubMed  CAS  Google Scholar 

  36. Nishimura MI, Kawakami Y, Charmley P, O’Neil B, Shilyansky J, Yannelli JR, Rosenberg SA, Hood L (1994) T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother Emphasis Tumor Immunol 16:85–94

    PubMed  CAS  Google Scholar 

  37. Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J (1989) Interaction of Staphylococcus aureus toxin “superantigens” with human T cells. Proc Natl Acad Sci USA 86:8941–8945

    Article  PubMed  CAS  Google Scholar 

  38. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P (1993) The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 90:4319–4323

    Article  PubMed  CAS  Google Scholar 

  39. Serrano D, Monteiro J, Allen SL, Kolitz J, Schulman P, Lichtman SM, Buchbinder A, Vinciguerra VP, Chiorazzi N, Gregersen PK (1997) Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 158:1482–1489

    PubMed  CAS  Google Scholar 

  40. Tsutsumi Y, Tanaka J, Miura Y, Toubai T, Kato N, Fujisaw F, Toyoshima N, Ota S, Mori A, Yonezumi M, Chiba K, Kondo T, Hasino S, Kobayasi R, Masauji N, Kasai M, Asaka M, Imamura M (2004) Molecular analysis of T-cell repertoire in patients with graft-versus-host disease after allogeneic stem cell transplantation. Leuk Lymphoma 45:481–488

    Article  PubMed  CAS  Google Scholar 

  41. Van De Corput L, Falkenburg JH, Kluin-Nelemans JC (1998) T-cell dysfunction in hairy cell leukemia: an updated review. Leuk Lymphoma 30:31–39

    PubMed  Google Scholar 

  42. Rocha B, Tanchot C (2004) CD8 T cell memory. Semin Immunol 16:305–314

    Article  PubMed  CAS  Google Scholar 

  43. Farace F, Orlanducci F, Dietrich PY, Gaudin C, Angevin E, Courtier MH, Bayle C, Hercend T, Triebel F (1994) T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol 153:4281–4290

    PubMed  CAS  Google Scholar 

  44. Rezvany MR, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H (1999) Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 94:1063–1069

    PubMed  CAS  Google Scholar 

  45. Alatrakchi N, Farace F, Frau E, Carde P, Munck JN, Triebel F (1998) T-cell clonal expansion in patients with B-cell lymphoproliferative disorders. J Immunother 21:363–370

    Article  PubMed  CAS  Google Scholar 

  46. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D (1997) The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 11:1312–1317

    Article  PubMed  CAS  Google Scholar 

  47. Molldrem JJ, LeePP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank technicians, nurses, patient care coordinators, and data managers from the Clinical Immunotherapy Section of the Laboratory of Molecular Biology, including Karen Bergeron, Kelly Cahill, Linda Ellison, Sonya Duke, Rita Mincemoyer, Barbara Debrah, and Inger Margulies. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Author information

Authors and Affiliations

  1. Laboratories of Molecular Biology and Pathology, and Biostatistics and Data Management Section, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Evgeny Arons, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Seth M. Steinberg, David J. Liewehr, Ira Pastan & Robert J. Kreitman

  2. Clinical Immunotherapy Section, Laboratory of Molecular Biology, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD, 20892-4255, USA

    Robert J. Kreitman

Authors
  1. Evgeny Arons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn Sorbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Raffeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maryalice Stetler-Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seth M. Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David J. Liewehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ira Pastan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert J. Kreitman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Kreitman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arons, E., Sorbara, L., Raffeld, M. et al. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol Immunother 55, 1100–1110 (2006). https://doi.org/10.1007/s00262-005-0099-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0099-1

Keywords

Search

Navigation